Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2008

Quintessence Retains Althea Technologies to Produce First Lead Candidate

  • Althea Technologies was awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.

    QBI-139 is effective in cancer models against a broad range of solid tumors, according to Quintessence. The company plans to file an IND for QBI-139 in the first quarter. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »